Most Recent Articles by Warren Ross
Call it the law of unintended consequences or the perfect storm or a bad hair day or any other cliché you can think of, but as 2009 came to a close we once again faced a cluster of bad news for the pharma industry.
American consumers are used to warranties. If you buy a TV set and it stops working within a specified time, you can ask for a replacement or to have it fixed.
Mr. Ross, when you headed KPR Informedia, did you submit articles to medical journals that were ghostwritten?
Pharma and biotech companies are competing to have enough vaccine on hand for the next swine flu (H1N1) outbreak. They missed the one last winter and spring, and their response has uniformly been: We'll be ready next time.
What the FDA euphemistically calls "guidances" are usually received by industry with something less than cheers. Despite the name, the guidances are often perceived as directives to be ignored at your peril.
More Articles by Warren Ross
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.